查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1771648

美國性傳染感染和陰道炎 PCR 檢測市場規模、佔有率、趨勢分析報告：疾病狀況、檢測類型、最終用途、細分市場預測，2025-2030 年

U.S. STI & Vaginitis PCR Testing Market Size, Share & Trends Analysis Report By Condition (Sexually Transmitted Infections (STIs), Vaginal Infections), By Test Type, By End Use, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

美國性傳染感染和陰道炎 PCR 檢測市場趨勢：

預計 2024 年美國性傳染感染和陰道炎 PCR 檢測市場規模將達到 2.4072 億美元，2025 年至 2030 年的複合年成長率為 8.2%。

性行為感染盛行率的不斷上升和患者意識的不斷提高推動了對先進診斷工具的需求。美國疾病管制與預防中心（CDC）每年持續報告數百萬例新的性傳染感染病例，其中最常見的是披衣菌感染、淋病和滴蟲病。感染疾病的增加迫切需要早期且準確的檢測方法。聚合酵素鏈鎖反應（PCR）檢測具有高靈敏度和特異性，是傳統診斷方法的可靠替代方法。由於患者和臨床醫生優先考慮快速且準確的結果，PCR 檢測在醫療設施更便利、檢測頻率更高的都市區中廣受歡迎，這進一步推動了市場擴張。與篩檢相關的恥辱感的逐漸減少也在鼓勵及時診斷方面發揮關鍵作用。

將PCR檢測納入診所和醫院的常規婦科和性衛生評估也是一個主要促進因素。許多醫療保健提供者現在建議高風險族群定期進行檢測，這增加了對基於PCR的解決方案的需求。就地檢驗和家用樣本採集試劑套件的日益流行，使得性傳染感染和陰道炎的檢測更加便捷。這些創新支持早期發現，並減少了與診所內檢測相關的障礙。因此，診斷實驗室和生物技術公司正在投資開發針對美國市場的易於使用的快速PCR套件。診斷公司和遠端醫療平台之間日益成長的夥伴關係關係擴大了PCR檢測服務的可近性。私人保險公司和雇主不斷增加的醫療保健支出也支持了先進診斷技術的廣泛應用。

多重PCR平台的技術進步正在提高性傳染感染和陰道炎檢測的效率。這些創新技術能夠同時檢測單一樣本中的多種病原體，從而降低成本並縮短檢測時間。這些技術進步對於管理性傳染感染患者中常見的合併感染尤其有效。此外，正在進行的微流體PCR設備和樣品製備自動化研究將提高實驗室的通量。這項進步將惠及面臨日益成長的檢測量的大型診斷網路和美國獨立實驗室。競爭格局也不斷演變，領先的公司正在推出針對難以檢測病原體的新型PCR檢測方法。隨著此類先進診斷方法的普及，整個市場的收益預計在2030年之前持續成長。

滴蟲病仍然是一個值得關注的問題，尤其對女性而言，最近的研究強調了它與不良妊娠結局的關係，這鼓勵了分子檢測的廣泛應用。單純皰疹病毒（HSV-1 和 HSV-2）由於其反覆發作和無症狀性排放而繼續被廣泛檢測，用於快速診斷的新型快速 PCR 檢測已獲得 FDA核准。人類乳突病毒 (HPV) 檢測對於識別與子宮頸癌和其他癌症相關的高風險病毒株至關重要，正如採用現代 FDA核准的HPV 檢測（如羅氏的 Cobas HPV 檢測）進行早期癌症篩檢所見。梅毒和其他性傳染感染雖然不太常見，但包含在多重檢測組中以確保全面篩檢和早期療育，多重 PCR 檢測組最近已在臨床試驗中得到檢驗，以提高靈敏度。

目錄

第1章調查方法與範圍

第2章執行摘要

第 3 章美國性傳染感染和陰道炎 PCR 檢測市場變數、趨勢和範圍

  • 市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析-波特五力分析
    • PESTLE分析

第4章美國性傳染感染與陰道炎 PCR 檢測市場：病理生理學商業分析

  • 2024年及2030年的疾病市場佔有率
  • 疾病細分儀表板
  • 市場規模、預測與趨勢分析（依疾病狀況，2018-2030 年）
  • 性行為感染感染（STI）
  • 陰道感染疾病

第5章美國性傳染感染與陰道炎 PCR 檢測市場：檢測類型業務分析

  • 2024 年和 2030 年測試類型市場佔有率
  • 考試類型細分儀表板
  • 按測試類型分類的市場規模、預測和趨勢分析（2018-2030 年）
  • STI PCR 檢測試劑盒
  • 陰道炎PCR檢測試劑盒

第6章美國性傳染感染和陰道炎 PCR 檢測市場：最終用途業務分析

  • 2024 年及 2030 年最終用途市場佔有率
  • 最終用途細分儀表板
  • 按最終用途分類的市場規模、預測和趨勢分析（2018-2030 年）
  • 醫院和診所
  • 診斷實驗室
  • 居家照護/居家檢測
  • 其他

第7章 競爭態勢

  • 參與者概覽
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Becton, Dickinson and Company（BD）
    • F. Hoffmann-La Roche Ltd.
    • Hologic, Inc.
    • Abbott
    • Danaher Corporation（Cepheid）
    • Seegene Inc.
    • bioMerieux（BioFire Diagnostics）
    • QIAGEN
    • Thermo Fisher Scientific, Inc.
    • DiaSorin SpA（Luminex）
    • Sansure Biotech Inc
    • R-Biopharm AG
    • altona Diagnostics GmbH
    • CERTEST BIOTEC.
Product Code: GVR-4-68040-615-9

U.S. STI & Vaginitis PCR Testing Market Trends:

The U.S. STI & vaginitis PCR testing market size was estimated at USD 240.72 million in 2024 and is projected to grow at a CAGR of 8.2% from 2025 to 2030. The increasing prevalence of sexually transmitted infections and growing patient awareness are driving demand for advanced diagnostic tools. The Centers for Disease Control and Prevention (CDC) continues to report millions of new STI cases each year, with chlamydia, gonorrhea, and trichomoniasis among the most reported. This rise in infections has created a pressing need for early and accurate detection methods. Polymerase chain reaction (PCR) tests provide high sensitivity and specificity, offering a reliable alternative to traditional diagnostics. As patients and clinicians prioritize quick and accurate results, PCR testing is gaining widespread preference in urban populations, with better access to healthcare facilities and higher testing frequencies, further supporting market expansion. The gradual decline in stigma related to STI screening also plays a vital role in encouraging timely diagnosis.

The integration of PCR testing into routine gynecological and sexual health evaluations in clinics and hospitals is another key driver. Many healthcare providers now recommend regular testing for at-risk populations, enhancing demand for PCR-based solutions. The growing trend of point-of-care testing and at-home sample collection kits has made STI and vaginitis testing more convenient. These innovations support early detection and reduce barriers associated with clinic-based testing. As a result, diagnostic labs and biotech firms are investing in developing user-friendly, rapid PCR kits tailored for the U.S. market. Rising partnerships between diagnostic companies and telehealth platforms expand access to PCR testing services. Increased healthcare spending by private insurers and employers also supports wider adoption of advanced diagnostic technologies.

Technological advancements in multiplex PCR platforms are improving the efficiency of STI and vaginitis testing. These innovations allow the simultaneous detection of multiple pathogens from a single sample, reducing costs and turnaround time. Such developments are particularly valuable for managing co-infections, which are common among patients with STIs. Furthermore, ongoing research into microfluidic PCR devices and automated sample preparation enhances laboratory throughput. This progress benefits large diagnostic networks and independent U.S. labs facing rising testing volumes. The competitive landscape is also evolving, with leading players launching novel PCR assays targeting hard-to-detect organisms. As these advanced diagnostics become more accessible, the overall market will witness consistent revenue growth through 2030.

Trichomoniasis remains a significant concern, especially in women, with recent studies emphasizing its link to adverse pregnancy outcomes, prompting wider use of molecular testing. Herpes Simplex Virus (HSV-1 & HSV-2) continues to see widespread testing due to its recurrent nature and asymptomatic shedding, with new rapid PCR assays gaining FDA approval for quicker diagnosis. Human Papillomavirus (HPV) testing is essential for identifying high-risk strains linked to cervical and other cancers, as seen in the adoption of the latest FDA-approved HPV assays like Roche's Cobas HPV test for early cancer screening. Syphilis and other STIs, though less common, are included in multiplex panels to ensure comprehensive detection and early intervention, with multiplex PCR panels recently validated in clinical studies for improved sensitivity.

U.S. STI & Vaginitis PCR Testing Market Report Segmentation

This report forecasts country revenue growth and analyzes the latest industry trends in each sub-segment from 2018 to 2030. For this study, Grand View Research has segmented the U.S. STI & vaginitis PCR testing market report based on condition, test type, and end use.

  • Condition Outlook (Revenue, USD Million, 2018 - 2030)
  • Sexually Transmitted Infections (STIs)
    • Chlamydia
    • Gonorrhea
    • Trichomoniasis
    • Herpes Simplex Virus (HSV-1 & HSV-2)
    • Human Papillomavirus (HPV)
    • Syphilis
    • Other
  • Vaginal Infections
    • Bacterial Vaginosis
    • Vulvovaginal Candidiasis
    • Others
  • Test Type Outlook (Revenue, USD Million, 2018 - 2030)
  • STI PCR Panels
  • Vaginitis PCR Panels
  • End Use Outlook (Revenue, USD Million, 2018 - 2030)
  • Hospitals and Clinics
  • Diagnostic Laboratories
  • Homecare/At-home Testing
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Condition
    • 1.2.2. Test Type
    • 1.2.3. End Use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. STI & Vaginitis PCR Testing Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. U.S. STI & Vaginitis PCR Testing Market: Condition Business Analysis

  • 4.1. Condition Market Share, 2024 & 2030
  • 4.2. Condition Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Condition, 2018 to 2030 (USD Million)
  • 4.4. Sexually Transmitted Infections (STIs)
    • 4.4.1. Sexually Transmitted Infections (STIs) Market, 2018 - 2030 (USD Million)
    • 4.4.2. Chlamydia
      • 4.4.2.1. Chlamydia Market, 2018 - 2030 (USD Million)
    • 4.4.3. Gonorrhea
      • 4.4.3.1. Gonorrhea Market, 2018 - 2030 (USD Million)
    • 4.4.4. Trichomoniasis
      • 4.4.4.1. Trichomoniasis Market, 2018 - 2030 (USD Million)
    • 4.4.5. Herpes Simplex Virus (HSV-1 & HSV-2
      • 4.4.5.1. Herpes Simplex Virus (HSV-1 & HSV-2) Market, 2018 - 2030 (USD Million)
    • 4.4.6. Human Papillomavirus (HPV)
      • 4.4.6.1. Human Papillomavirus (HPV) Market, 2018 - 2030 (USD Million)
    • 4.4.7. Syphilis
      • 4.4.7.1. Syphilis Market, 2018 - 2030 (USD Million)
    • 4.4.8. Other
      • 4.4.8.1. Other Market, 2018 - 2030 (USD Million)
  • 4.5. Vaginal Infections
    • 4.5.1. Vaginal Infections Market, 2018 - 2030 (USD Million)
    • 4.5.2. Bacterial Vaginosis
      • 4.5.2.1. Bacterial Vaginosis Market, 2018 - 2030 (USD Million)
    • 4.5.3. Vulvovaginal Candidiasis
      • 4.5.3.1. Vulvovaginal Candidiasis Market, 2018 - 2030 (USD Million)
    • 4.5.4. Others
      • 4.5.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. U.S. STI & Vaginitis PCR Testing Market: Test Type Business Analysis

  • 5.1. Test Type Market Share, 2024 & 2030
  • 5.2. Test Type Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Test Type, 2018 to 2030 (USD Million)
  • 5.4. STI PCR Panels
    • 5.4.1. STI PCR Panels Market, 2018 - 2030 (USD Million)
  • 5.5. Vaginitis PCR Panels
    • 5.5.1. Vaginitis PCR Panels Market, 2018 - 2030 (USD Million)

Chapter 6. U.S. STI & Vaginitis PCR Testing Market: End Use Business Analysis

  • 6.1. End Use Market Share, 2024 & 2030
  • 6.2. End Use Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Hospitals and Clinics
    • 6.4.1. Hospitals and Clinics, 2018 - 2030 (USD Million)
  • 6.5. Diagnostic Laboratories
    • 6.5.1. Diagnostic Laboratories Market, 2018 - 2030 (USD Million)
  • 6.6. Homecare/At-home Testing
    • 6.6.1. Homecare/At-home Testing Market, 2018 - 2030 (USD Million)
  • 6.7. Others
    • 6.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Becton, Dickinson and Company (BD)
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Type Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. F. Hoffmann-La Roche Ltd.
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Type Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Hologic, Inc.
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Type Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Abbott
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Type Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Danaher Corporation (Cepheid)
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Type Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Seegene Inc.
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Type Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. bioMerieux (BioFire Diagnostics)
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Type Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. QIAGEN
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Type Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Thermo Fisher Scientific, Inc.
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Type Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. DiaSorin S.p.A (Luminex)
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Type Benchmarking
      • 7.5.10.4. Strategic Initiatives
    • 7.5.11. Sansure Biotech Inc
      • 7.5.11.1. Overview
      • 7.5.11.2. Financial Performance
      • 7.5.11.3. Type Benchmarking
      • 7.5.11.4. Strategic Initiatives
    • 7.5.12. R-Biopharm AG
      • 7.5.12.1. Overview
      • 7.5.12.2. Financial Performance
      • 7.5.12.3. Type Benchmarking
      • 7.5.12.4. Strategic Initiatives
    • 7.5.13. altona Diagnostics GmbH
      • 7.5.13.1. Overview
      • 7.5.13.2. Financial Performance
      • 7.5.13.3. Type Benchmarking
      • 7.5.13.4. Strategic Initiatives
    • 7.5.14. CERTEST BIOTEC.
      • 7.5.14.1. Overview
      • 7.5.14.2. Financial Performance
      • 7.5.14.3. Type Benchmarking
      • 7.5.14.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. STI & vaginitis PCR testing market, by condition, 2018 - 2030 (USD Million)
  • Table 4 U.S. STI & vaginitis PCR testing market, by test type, 2018 - 2030 (USD Million)
  • Table 5 U.S. STI & vaginitis PCR testing market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 U.S. STI & vaginitis PCR testing market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Condition outlook (USD Million)
  • Fig. 10 Test Type outlook (USD Million)
  • Fig. 11 End Use outlook (USD Million)
  • Fig. 12 Competitive landscape
  • Fig. 13 U.S. STI & vaginitis PCR testing market dynamics
  • Fig. 14 U.S. STI & vaginitis PCR testing market: Porter's five forces analysis
  • Fig. 15 U.S. STI & vaginitis PCR testing market: PESTLE analysis
  • Fig. 16 U.S. STI & vaginitis PCR testing market: Condition segment dashboard
  • Fig. 17 U.S. STI & vaginitis PCR testing market: Condition market share analysis, 2024 & 2030
  • Fig. 18 Sexually Transmitted Infections (STIs) market, 2018 - 2030 (USD Million)
  • Fig. 19 Chlamydia market, 2018 - 2030 (USD Million)
  • Fig. 20 Gonorrhea market, 2018 - 2030 (USD Million)
  • Fig. 21 Trichomoniasis market, 2018 - 2030 (USD Million)
  • Fig. 22 Herpes Simplex Virus (HSV-1 & HSV-2) market, 2018 - 2030 (USD Million)
  • Fig. 23 Human Papillomavirus (HPV) market, 2018 - 2030 (USD Million)
  • Fig. 24 Syphilis market, 2018 - 2030 (USD Million)
  • Fig. 25 Other market, 2018 - 2030 (USD Million)
  • Fig. 26 Vaginal infections market, 2018 - 2030 (USD Million)
  • Fig. 27 Bacterial vaginosis market, 2018 - 2030 (USD Million)
  • Fig. 28 Vulvovaginal candidiasis market, 2018 - 2030 (USD Million)
  • Fig. 29 Others market, 2018 - 2030 (USD Million)
  • Fig. 30 U.S. STI & vaginitis PCR testing market: Test Type segment dashboard
  • Fig. 31 U.S. STI & vaginitis PCR testing market: Test Type market share analysis, 2024 & 2030
  • Fig. 32 STI PCR panels market, 2018 - 2030 (USD Million)
  • Fig. 33 Vaginitis PCR panels market, 2018 - 2030 (USD Million)
  • Fig. 34 U.S. STI & vaginitis PCR testing market: End use segment dashboard
  • Fig. 35 U.S. STI & vaginitis PCR testing market: End use market share analysis, 2024 & 2030
  • Fig. 36 Hospitals and clinics market, 2018 - 2030 (USD Million)
  • Fig. 37 Diagnostic laboratories market, 2018 - 2030 (USD Million)
  • Fig. 38 Homecare/at-home testing market, 2018 - 2030 (USD Million)
  • Fig. 39 Others market, 2018 - 2030 (USD Million)
  • Fig. 40 Company categorization
  • Fig. 41 Company market position analysis
  • Fig. 42 Strategic framework